Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

Shan L, Chen YA, Davis L, Han G, Zhu W, Molina AD, Arango H, LaPolla JP, Hoffman MS, Sellers T, Kirby T, Nicosia SV, Sutphen R.

PLoS One. 2012;7(10):e46846. doi: 10.1371/journal.pone.0046846. Epub 2012 Oct 17.

2.

Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.

Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R.

Int J Gynecol Cancer. 2010 Dec;20(9):1518-24.

PMID:
21370595
3.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

4.

Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM.

PLoS One. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. eCollection 2015.

5.

Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.

Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.

Ginekol Pol. 2015 Feb;86(2):88-93.

PMID:
25807831
6.

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.

Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.

Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.

7.

Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr.

Gynecol Oncol. 2011 Sep;122(3):548-53. doi: 10.1016/j.ygyno.2011.06.002. Epub 2011 Jun 25.

8.

The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.

Zou L, He X, Zhang JW.

Braz J Med Biol Res. 2010 Dec;43(12):1232-8. Epub 2010 Nov 26.

9.

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E.

PLoS One. 2016 Oct 31;11(10):e0165609. doi: 10.1371/journal.pone.0165609. eCollection 2016.

10.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

11.

Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.

Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):621-8. Epub 2007 Sep 14.

PMID:
17868339
12.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

13.

Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.

Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M.

Arch Gynecol Obstet. 2013 Oct;288(4):859-65. doi: 10.1007/s00404-013-2819-7. Epub 2013 Apr 7.

PMID:
23564055
14.

[Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].

Zhao BB, Yang ZJ, Wang Q, Pan ZM, Zhang W, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):11-19. doi: 10.3760/cma.j.issn.0529-567X.2017.01.005. Chinese.

PMID:
28190310
15.

The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.

Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075. Epub 2011 Feb 3.

PMID:
21288178
16.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

17.

A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.

Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Høyer-Hansen G, Borgfeldt C.

Anticancer Res. 2016 Mar;36(3):957-65.

PMID:
26976984
18.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
19.

Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.

Pearl ML, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, Golightly M, Zucker S, Chen WT.

Gynecol Oncol. 2014 Sep;134(3):581-90. doi: 10.1016/j.ygyno.2014.06.013. Epub 2014 Jun 24.

20.

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2013 Sep;51(9):1815-24. doi: 10.1515/cclm-2013-0151.

PMID:
24013103

Supplemental Content

Support Center